Delta F508 Mutation
Delta F508 Mutation - Related Videos
01:17
The Delta-to-Delta Circuit
0 Views •
2024
In a delta-delta configuration, the source and the load are connected in a delta manner, forming a closed loop that divides the network into three distinct phases. This configuration makes the phase voltages identical to line voltages. Assuming the sources are in positive sequence, the phase voltages can be expressed directly without having a neutral wire. The phase currents in a delta-connected load are calculated by dividing the phase voltage by the load impedance per phase: In this...
05:47
Intravital Visualization of Gamma Delta Intraepithelial Lymphocytes
0 Views •
2025
This video demonstrates the visualization of γδ intraepithelial lymphocytes (IELs) in transgenic mice using confocal microscopy. The surgical procedure involves creating a perforation line and making a longitudinal incision to expose the intestinal mucosa and villi. The transgenic mice express reporter proteins exclusively in γδ IELs, allowing their tracking. Intravital imaging captures the dynamic movement of green fluorescence-labeled γδ IELs along the intestinal epithelial cell's basement...
01:19
The Y-to-Delta Circuit
0 Views •
2024
A balanced wye-to-delta circuit comprises balanced Y-connected voltage sources and delta-connected loads with no neutral line connection. The initial step in analyzing a wye-to-delta circuit is to assume a positive phase sequence. These phase voltages are then utilized to calculate the line voltages that occur directly across the delta-connected load impedances. Van, Vbn, and Vcn are the phase voltages in wye, and Vab, Vbc, and Vca are the line voltages for a delta circuit. The relation between...
01:16
The Delta-to-Y Circuit
0 Views •
2024
In the delta-wye circuit, the source is delta-connected, while the load is in a wye configuration. This means that the phase voltage of the delta-connected source is equal to the line voltage of the wye-connected load. The connection between two-line currents originates from the delta-connected source. The phase difference in the balanced system allows for calculating one line current given the other, utilizing the positive sequence of phases. In the delta-wye system, the phase currents in the...
00:36
Viral Mutations
0 Views •
2019
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
FAQs
The two drug actions address different pharmacological limitations: correctors improve the mutant protein’s folding and delivery to the plasma membrane, whereas potentiators enhance opening of CFTR channels that reach the cell surface. Combining them can therefore improve both channel abundance and activity, producing greater restoration of epithelial ion transport than targeting either step alone.
Quality-control systems identify the destabilized protein as unsuitable and direct much of it toward degradation, limiting the amount available for correction at the cell surface. A corrector must therefore influence the protein before or during trafficking, while a potentiator can act only on channels that successfully reach the membrane. This distinction explains their complementary roles.
Because the delivered protein may retain abnormal chloride-channel function rather than being completely inactive. That residual population provides a target for potentiation, while the trafficking defect remains a separate target for correction. Recognizing both defects helps explain why treatment design focuses on improving protein delivery and channel performance together.
The specific CFTR variant indicates which molecular defect a therapy must address. For F508del, treatment can be designed around impaired folding and trafficking, together with abnormal channel function in the protein that reaches the membrane. This genotype-linked logic supports precision treatment instead of treating all CFTR-related disease as pharmacologically identical.
The key outcome is improved epithelial ion transport, reflecting more functional CFTR activity at the plasma membrane. In the broader therapeutic context, this cellular change is relevant because it can accompany reduced disease burden. Thus, pharmacology connects molecular rescue of CFTR with a functional consequence that helps assess whether treatment benefits extend beyond protein processing.
It links a single CFTR variant to multiple pharmacological intervention points, including protein folding, trafficking, and channel opening. This makes it useful for examining whether correctors, potentiators, or their combinations address distinct stages of dysfunction. Studying these linked outcomes also supports genotype-based treatment design and connects molecular mechanisms with epithelial ion transport and disease burden.